Evidence map›Paper›PMID 31139324›Full record

ArticleOncotarget2019

Gender differences in cancer risk after kidney transplantation.

Anna Buxeda, Dolores Redondo-Pachón, María José Pérez-Sáez, Álvaro Bartolomé, Marisa Mir, Ana Pascual-Dapena, Anna Sans, Xavier Duran, Marta Crespo, Julio Pascual

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Gender and kidney transplantation.Frontiers in nephrology · 2024
    Review
  9. Review
  10. Observational
  11. Pelvic radiation therapy with volumetric modulated arc therapy and intensity-modulated radiotherapy after renal transplant: A report of 3 cases.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Anna BuxedaDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
Dolores Redondo-PachónDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
María José Pérez-SáezDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
Álvaro BartoloméDepartment of Medicine, University Autonoma Barcelona, Barcelona, Spain.
Marisa MirDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
Ana Pascual-DapenaDepartment of Medicine, University Autonoma Barcelona, Barcelona, Spain.
Anna SansDepartment of Medicine, University Autonoma Barcelona, Barcelona, Spain.
Xavier DuranMethodology and Biostatistics Support Unit, Institute Hospital del Mar for Medical Research (IMIM), Barcelona, Spain.
Marta CrespoDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
Julio PascualDepartment of Nephrology, Hospital del Mar, Barcelona, Spain.
Hospital Del Mar · ESPompeu Fabra University · ESUniversitat Autònoma de Barcelona · ESMunicipal Institute for Medical Research · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Kidney transplant (KT) recipients are at greater risk of developing some cancers than the general population. Moreover, cancer is the only cause of death that is currently increasing after kidney transplantation. We analyzed incidence, risk factors and characteristics of post-transplant malignancies (solid organ tumors and lymphoproliferative disorders) at our center in 925 KT recipients (1979-2014). Sex differences were particularly assessed. One hundred and eight patients (11.7%) developed solid organ tumors (76.9%) or lymphoma (23.1%). Twenty-one percent of patients who reached 20 years after KT developed cancer, with a median post-KT time to diagnosis of 7.4 years. Most common solid organs affected were lung (30.1%), prostate (10.8%), bladder (9.6%), and native kidney (7.2%). When analyzing standardized incidence ratios (SIR) by gender compared to the general population, relative risk was increased in women (SIR = 1.81; 95%CI, 1.28-2.45) but not significantly increased in men (SIR = 1.22; 0.95-2.52). Regarding specific types, gynecological (SIR = 11.6; 4.2-22.7) and lung (SIR = 10.0; 4.3-18.2) in women, and bladder (SIR = 16.3; 5.9-32.1) in men were the most affected locations. Thymoglobulin, a polyclonal antibody that has been used as an immunosuppressive agent in kidney transplantation over the last decades, was a significant risk factor for developing cancer in adjusted regression analysis [IRR = 1.62, 1.02-2.57; p = 0.041], and was associated with lower patient survival. Compared with the general population, the incidence of post-KT non-skin cancer is almost two-fold higher in women but not significantly higher in men. Lung is the most common solid organ affected. Thymoglobulin induction therapy is associated with a greater risk.

Indexed as

cancergenderimmunosuppressionkidney transplantrisk factor

Identifiers

PMID31139324
PMCPMC6517099
OpenAlexW2943012430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.